The Two Humanoid-Robot Funds Are 30 Points Apart This Year. The Winner Owns the Parts, Not the Promises

HUMN’s humanoid concentration backfired: it has given back ~26% in July and is only up +11.0% YTD versus KOID’s +41.8% over the same period. The ETF’s top two holdings (Tesla at 8.93% and UBTech Robotics at 6.42%) account for nearly 15% of assets and both dropped sharply mid-year, while KOID’s more diversified construction and lower stated fees (0.79% gross / 0.69% net) have helped it outperform. For investors, the article suggests a cleaner swap in tax-advantaged accounts and notes that HUMN outperformance depends on a recovery in its marquee names.

Analysis

This is less a commentary on humanoid robotics than on portfolio construction risk. KOID is the cleaner way to own the theme because it monetizes breadth in an emerging supply chain, while HUMN behaves like a concentrated venture basket with one or two names dominating short-term P&L. In a market that is still rewarding “theme” exposure but punishing single-name disappointment, the diversified vehicle should continue to attract incremental flows over the next 1-3 months.

The second-order winner is not necessarily the robot OEMs but the enablers: compute, motion control, and test/automation spend should compound even if headline robot adoption stalls. That makes NVDA and TER better structural expressions of the buildout than brand-heavy wrappers, because their revenues are tied to capex intensity rather than consumer sentiment around any one robot platform. HUMN only regains leadership if the marquee names move from narrative to visible shipments.

The key risk to a relative short-HUMN view is a catalyst reset from Tesla or UBTech that re-prices the whole segment within days. If product milestones, delivery data, or manufacturing updates improve, HUMN’s concentration turns from a drag into convexity and the spread can reverse sharply; the falsifier is a sustained rebound in the top holdings rather than broad theme enthusiasm. Longer term, if humanoids become a real industrial spend cycle, supplier-heavy baskets should win on durability even if the early brand leaders remain volatile.

Contrarian take: the market may already be over-penalizing HUMN for exactly what makes it valuable—purity. In a speculative theme, concentration can outperform for long stretches because capital wants the highest-beta expression, so the underperformance is not automatically a buying opportunity. That said, for investors seeking physical-AI exposure without single-name blowup risk, KOID is the better core vehicle and HUMN is better treated as tactical exposure.

Key Decisions for Investors

• Long KOID / short HUMN for 1-3 months as a relative-value pair trade; target KOID outperforming by 8-15 points, stop if HUMN outperforms by 5 points on a product/news-driven squeeze.
• In tax-advantaged accounts, rotate HUMN into KOID now to preserve theme exposure while reducing single-name beta; this is the cleanest implementation if the goal is physical AI rather than brand risk.
• If retaining HUMN, hedge idiosyncratic beta by shorting TSLA into known catalyst windows; this strips out the largest concentration risk and leaves you with a purer theme exposure.
• Prefer NVDA and TER over either ETF for a 6-18 month structural view on humanoid capex; buy on weakness if you want the enabler trade rather than the narrative trade.
• Treat HUMN as tactical only: add only on confirmed shipment/production inflection, and de-risk if no evidence of commercialization appears within the next 1-2 quarters.